Unknown

Dataset Information

0

TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.


ABSTRACT: Agonists for TLR9 and Stimulator of IFN Gene (STING) act as vaccine adjuvants that induce type-1 immune responses. However, currently available CpG oligodeoxynucleotide (ODN) (K-type) induces IFNs only weakly and STING ligands rather induce type-2 immune responses, limiting their potential therapeutic applications. Here, we show a potent synergism between TLR9 and STING agonists. Together, they make an effective type-1 adjuvant and an anticancer agent. The synergistic effect between CpG ODN (K3) and STING-ligand cyclic GMP-AMP (cGAMP), culminating in NK cell IFN-? (type-II IFN) production, is due to the concurrent effects of IL-12 and type-I IFNs, which are differentially regulated by IRF3/7, STING, and MyD88. The combination of CpG ODN with cGAMP is a potent type-1 adjuvant, capable of inducing strong Th 1-type responses, as demonstrated by enhanced antigen-specific IgG2c and IFN-? production, as well as cytotoxic CD8(+) T-cell responses. In our murine tumor models, intratumoral injection of CpG ODN and cGAMP together reduced tumor size significantly compared with the singular treatments, acting as an antigen-free anticancer agent. Thus, the combination of CpG ODN and a STING ligand may offer therapeutic application as a potent type-II IFN inducer.

SUBMITTER: Temizoz B 

PROVIDER: S-EPMC4671267 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.

Temizoz Burcu B   Kuroda Etsushi E   Ohata Keiichi K   Jounai Nao N   Ozasa Koji K   Kobiyama Kouji K   Aoshi Taiki T   Ishii Ken J KJ  

European journal of immunology 20150205 4


Agonists for TLR9 and Stimulator of IFN Gene (STING) act as vaccine adjuvants that induce type-1 immune responses. However, currently available CpG oligodeoxynucleotide (ODN) (K-type) induces IFNs only weakly and STING ligands rather induce type-2 immune responses, limiting their potential therapeutic applications. Here, we show a potent synergism between TLR9 and STING agonists. Together, they make an effective type-1 adjuvant and an anticancer agent. The synergistic effect between CpG ODN (K3)  ...[more]

Similar Datasets

| S-EPMC7477748 | biostudies-literature
| S-EPMC5451393 | biostudies-literature
| S-EPMC7430760 | biostudies-literature
| S-EPMC4835894 | biostudies-literature
| S-EPMC4285460 | biostudies-literature
| S-EPMC7460725 | biostudies-literature
| S-EPMC5216379 | biostudies-literature
| S-EPMC4855687 | biostudies-literature
| S-EPMC10611477 | biostudies-literature
| S-EPMC5533512 | biostudies-literature